IN THE NEWS

BOTHELL, WA – Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, announced today it has completed its pilot program and has begun full shipments of its new “crash cart” defibrillator as part of an existing agreement with GE Healthcare (GE).

The crash cart defibrillator-monitor is designed specifically for use by medical professionals to respond to cardiac emergencies in hospital settings. The new defibrillator will be manufactured by Cardiac Science and sold exclusively by GE to hospitals in the United States and Canada as the Cardiac Science Powerheart^® ECD, and to customers outside North America as the GE Responder™2000. GE will be featuring the product at the upcoming American Heart Association (AHA) and MEDICA trade shows in November.

“The new defibrillator-monitor meets the demanding requirements for hospital use, and demonstrates our continuing efforts to broaden our products and services. We believe this crash cart is a compelling offering for the estimated $300 million worldwide hospital defibrillator-monitor market,” said John Hinson, Cardiac Science’s Chief Executive Officer.  “Our partnership with GE will give us the reach and scope to effectively penetrate that market, and contribute to our goal of saving more lives. If the initial indications are a measure of market acceptance, we believe this product will very successful for both companies.”

The defibrillators are currently available outside of North America, and are expected to be available within the U.S. and Canada during the first quarter of 2008.

About the new defibrillator-monitor

The new defibrillator-monitor is a lightweight, rugged and portable device designed for use by professionals in medically-supervised environments to respond to cardiac emergencies.  Similar to Cardiac Science’s line of portable AEDs, the new device is extremely easy to use, while still incorporating advanced resuscitation and pacing therapies for use by the trained medical professional.

The new defibrillator-monitor incorporates Cardiac Science’s patented STAR^® biphasic escalating shock energy technology which automatically adjusts the magnitude of the defibrillation shock based upon each patient’s unique body type.  It also employs Cardiac Science’s patented RHYTHMx^® software, which provides heart rhythm analysis and shock advice to effectively address life-threatening arrhythmias.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif